Phio Pharmaceuticals is using RNA interference (RNAi) technology to make immune cells more effective in killing tumor cells. RNAi uses short-interfering RNAs (siRNAs) that recognise specific mRNA molecules and prevent them from making protein. Using their INTASYL patented precision delivery technology, Phio is creating uniquely modified siRNA compounds that are designed to silence a broad range of gene targets in the human genome. Phio’s INTASYL compounds can enter tumor and immune cells and be administered intratumorally or topically. PH-762, is Phio’s lead program that is in clinical trials for treating cutaneous squamous cell carcinoma. The therapy silences the protein PD-1 which inhibits T cells abilities to kill cancer cells.

Phio Pharmaceuticals

Founded: 2011
Location: Marlborough, MA
Employee range: 1 - 10
Clinical stage: Clin0
Therapy area: Multiple cancers
Drug types: ONC
Lead product: PH-762
Funding: $4M stock Jun 2023; $2M stock Apr 2023; $7.7M stock Feb 2021; $14M stock Jan 2021; $4M stock Apr 2020; $1.74M stock Feb 2020; $1M stock Nov 2019

Drug notes:

About:

Jobs: